LUMO Projected Dividend Yield
Lumos Pharma Inc ( NASDAQ : LUMO )Lumos Pharma is a clinical-stage biopharmaceutical company. Co. is engaged in developing its clinical program and focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Co.'s pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone secretagogue, also called ibutamoren, for rare endocrine disorders where injectable recombinant human growth hormone is approved. Co. has two small-molecule product candidates, which include indoximod, NLG802 (a prodrug of indoximod) and NLG919 (a direct IDO1 enzymatic inhibitor) that are indoleamine-2, 3-dioxygenase pathway inhibitors. 20 YEAR PERFORMANCE RESULTS |
LUMO Dividend History Detail LUMO Dividend News LUMO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |